Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na

Leukemia Research

Volumn 36, Issue 8, 2012, Pages 982-989

  Olnes, Matthew J ^a,b   Shenoy, Aarthie ^a   Weinstein, Barbara ^a   Pfannes, Loretta ^a   Loeliger, Kelsey ^a   Tucker, Zachary ^a   Tian, Xin ^a   Kwak, Minjung ^a   Wilhelm, Francois ^c   Yong, Agnes S M ^a   Maric, Irina ^e   Maniar, Manoj ^c   Scheinberg, Phillip ^a   Groopman, Jerome ^d   Young, Neal S ^a   Sloand, Elaine M ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b ALASKA NATIVE TRIBAL HEALTH CONSORTIUM   (United States)

^c Onconova Therapeutics Inc   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Cyclin D1; MDS; ON 01910.Na; Treatment

Indexed keywords

CYCLIN D1; ON 01910 NA; RIGOSERTIB; UNCLASSIFIED DRUG;

ADULT; AGED; ANEUPLOIDY; ARTICLE; BACTEREMIA; BLEEDING; BONE MARROW BIOPSY; BONE MARROW CELL; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONJUNCTIVITIS; CONTINUOUS INFUSION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; EPISTAXIS; FEBRILE NEUTROPENIA; FEMALE; FLOW CYTOMETRY; GINGIVA BLEEDING; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEMATURIA; HUMAN; HUMAN TISSUE; HYPOTENSION; IN VITRO STUDY; INFLAMMATION; MALE; MONONUCLEAR CELL; MONOSOMY 7; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; PAIN; PHARYNGITIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATITIS; PROTEIN EXPRESSION; RADIATION INJURY; RNA INTERFERENCE; SIDE EFFECT; THORAX PAIN; THRUSH; TRISOMY 8; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

AGED; AGED, 80 AND OVER; ALGORITHMS; ANTINEOPLASTIC AGENTS; BONE MARROW CELLS; CHROMOSOMES, HUMAN, PAIR 8; CYCLIN D1; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLYCINE; HUMANS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MYELODYSPLASTIC SYNDROMES; SULFONES; TRISOMY; TUMOR CELLS, CULTURED;

EID: 84862572347     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.04.002     Document Type: Article

References (31)

1. Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
2. Ma X., Does M., Raza A., Mayne S.T. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 2007, 109:1536-1542.
3. Nimer S.D. Myelodysplastic syndromes. Blood 2008, 111:4841-4851.
4. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10:223-232.
5. List A., Kurtin S., Roe D.J., et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005, 352:549-557.
6. Ades L., Boehrer S., Prebet T., et al. Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. Blood 2009, 113:3947-3952.
7. Haase D., Germing U., Schanz J., et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007, 110:4385-4395.
8. Schoch C., Kohlmann A., Dugas M., et al. Genomic gains and losses influence expression levels of genes located within the affected regions: a study on acute myeloid leukemias with trisomy 8, 11, or 13, monosomy 7, or deletion 5q. Leukemia 2005, 19:1224-1228.
9. Chen G., Zeng W., Miyazato A., et al. Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities. Blood 2004, 104:4210-4218.
10. Sloand E.M., Pfannes L., Chen G., et al. CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins. Blood 2007, 109:2399-2405.
11. Saberwal G., Broderick E., Janssen I., et al. Involvement of cyclin D1 and E2F1 in intramedullary apoptosis in myelodysplastic syndromes. J Hematother Stem Cell Res 2003, 12:443-450.
12. Jaroslav P., Martina H., Jiri S., et al. Expression of cyclins D1, D2, and D3 and Ki-67 in leukemia. Leuk Lymphoma 2005, 46:1605-1612.
13. Economopoulou C., Pappa V., Papageorgiou S., et al. Cell cycle and apoptosis regulatory gene expression in the bone marrow of patients with de novo myelodysplastic syndromes (MDS). Ann Hematol 2010, 89:349-358.
14. Bortul R., Tazzari P.L., Cappellini A., et al. Constitutively active Akt1 protects HL60 leukemia cells from TRAIL-induced apoptosis through a mechanism involving NF-kappaB activation and cFLIP(L) up-regulation. Leukemia 2003, 17:379-389.
15. Sloand E.M., Mainwaring L., Fuhrer M., et al. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 2005, 106:841-851.
16. Prasad A., Park I.W., Allen H., et al. Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells. Oncogene 2009, 28:1518-1528.
17. Chun A., Cosenza S., Taft D., Maniar M. Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent. Cancer Chemother Pharmacol 2010, 9:1022-1029.
18. Jimeno A., Li J., Messersmith W.A., et al. Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. J Clin Oncol 2008, 26:5504-5510.
19. Sloand E.M., Yong A.S., Ramkissoon S., et al. Granulocyte colony-stimulating factor preferentially stimulates proliferation of monosomy 7 cells bearing the isoform IV receptor. Proc Natl Acad Sci USA 2006, 103:14483-14488.
20. Beillard E., Pallisgaard N., van der Velden V.H., et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia 2003, 17:2474-2486.
21. Yong A.S., Szydlo R.M., Goldman J.M., Apperley J.F., Melo J.V. Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. Blood 2006, 107:205-212.
22. Sloand E.M., Fuhrer M., Keyvanfar K., et al. Cytogenetic abnormalities in paroxysmal nocturnal haemoglobinuria usually occur in haematopoietic cells that are glycosylphosphatidylinositol-anchored protein (GPI-AP) positive. Br J Haematol 2003, 123:173-176.
23. Myelodysplastic syndromes. WHO classification of tumours of haematopoietic and lymphoid tissues 2010, IARC, Lyon. fourth ed. S.H. Swerdlow (Ed.).
24. Storer B.E. Design and analysis of phase I clinical trials. Biometrics 1989, 45:925-937.
25. Cheson B.D., Greenberg P.L., Bennett J.M., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006, 108:419-425.
26. Li J., Zhao M., Jimeno A., et al. Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ON 01910.Na, a mitotic progression modulator, in human plasma. J Chromatogr B: Analyt Technol Biomed Life Sci 2007, 856:198-204.
27. Malcovati L., Germing U., Kuendgen A., et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007, 25:3503-3510.
28. Olnes M.J., Sloand E.M. Targeting immune dysregulation in myelodysplastic syndromes. JAMA 2011, 305:814-819.
29. El-Ouriaghli F., Sloand E., Mainwaring L., et al. Clonal dominance of chronic myelogenous leukemia is associated with diminished sensitivity to the antiproliferative effects of neutrophil elastase. Blood 2003, 102:3786-3792.
30. Colmone A., Amorim M., Pontier A.L., Wang S., Jablonski E., Sipkins D.A. Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science 2008, 322:1861-1865.
31. Seetharam M., Fan A.C., Tran M., et al. Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na. Leukemia Res 2012, 36:98-103.